Pleomorphic lobular carcinoma in situ of the breast: Clinicopathological review of 47 cases

Thaer Khoury, Rouzan G. Karabakhtsian, David Mattson, Li Yan, Susanna Syriac, Fadi Habib, Song Liu, Mohamed M. Desouki

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Aims: Pleomorphic lobular carcinoma in situ (PLCIS) of the breast is a distinctive entity, but its behaviour and management are unclear. The purpose of this study was to review a relatively large number of cases and to evaluate the risk of recurrence. Methods and results: Cases of PLCIS (n = 47) from a 12-year period were reviewed. The clinical, radiological and pathological findings were recorded. Immunohistochemistry for oestrogen receptor (ER), progesterone receptor (PR) and HER2 was performed. Thirty-one patients had no concurrent breast cancer or past history of breast cancer, and six (19.4%) of these had local recurrence; all tumours (four invasive carcinoma and two PLCIS) were ipsilateral. Younger age at presentation was a risk factor for local recurrence: patients with recurrence had a mean age (range) of 52.5 years (44-59 years), versus 60.6 years (40-81 years) for those without (P = 0.03). Three of 31 patients were treated with radiation therapy (RT), and none of these developed local recurrence. PLCIS had an adverse ER/PR/HER2 molecular profile, with at least 41.2% of the cases overexpressing HER2. Moreover, at least 11.7% of the cases were triple-negative. Conclusions: This study included the largest number of patients who had no concurrent breast cancer or past history of breast cancer with the longest clinical follow-up, providing insights into management practices for PLCIS and the risk of recurrence.

Original languageEnglish (US)
Pages (from-to)981-993
Number of pages13
JournalHistopathology
Volume64
Issue number7
DOIs
StatePublished - 2014

Fingerprint

Breast
Recurrence
Breast Neoplasms
Progesterone Receptors
Practice Management
Estrogen Receptors
Breast Carcinoma In Situ
Radiotherapy
Immunohistochemistry
Carcinoma
Neoplasms

Keywords

  • Adjuvant therapy
  • Breast
  • Local recurrence
  • Pleomorphic lobular carcinoma in situ

ASJC Scopus subject areas

  • Histology
  • Pathology and Forensic Medicine

Cite this

Pleomorphic lobular carcinoma in situ of the breast : Clinicopathological review of 47 cases. / Khoury, Thaer; Karabakhtsian, Rouzan G.; Mattson, David; Yan, Li; Syriac, Susanna; Habib, Fadi; Liu, Song; Desouki, Mohamed M.

In: Histopathology, Vol. 64, No. 7, 2014, p. 981-993.

Research output: Contribution to journalArticle

Khoury, T, Karabakhtsian, RG, Mattson, D, Yan, L, Syriac, S, Habib, F, Liu, S & Desouki, MM 2014, 'Pleomorphic lobular carcinoma in situ of the breast: Clinicopathological review of 47 cases', Histopathology, vol. 64, no. 7, pp. 981-993. https://doi.org/10.1111/his.12353
Khoury, Thaer ; Karabakhtsian, Rouzan G. ; Mattson, David ; Yan, Li ; Syriac, Susanna ; Habib, Fadi ; Liu, Song ; Desouki, Mohamed M. / Pleomorphic lobular carcinoma in situ of the breast : Clinicopathological review of 47 cases. In: Histopathology. 2014 ; Vol. 64, No. 7. pp. 981-993.
@article{35de48ab53d44759bdad8f7d8f29a6a6,
title = "Pleomorphic lobular carcinoma in situ of the breast: Clinicopathological review of 47 cases",
abstract = "Aims: Pleomorphic lobular carcinoma in situ (PLCIS) of the breast is a distinctive entity, but its behaviour and management are unclear. The purpose of this study was to review a relatively large number of cases and to evaluate the risk of recurrence. Methods and results: Cases of PLCIS (n = 47) from a 12-year period were reviewed. The clinical, radiological and pathological findings were recorded. Immunohistochemistry for oestrogen receptor (ER), progesterone receptor (PR) and HER2 was performed. Thirty-one patients had no concurrent breast cancer or past history of breast cancer, and six (19.4{\%}) of these had local recurrence; all tumours (four invasive carcinoma and two PLCIS) were ipsilateral. Younger age at presentation was a risk factor for local recurrence: patients with recurrence had a mean age (range) of 52.5 years (44-59 years), versus 60.6 years (40-81 years) for those without (P = 0.03). Three of 31 patients were treated with radiation therapy (RT), and none of these developed local recurrence. PLCIS had an adverse ER/PR/HER2 molecular profile, with at least 41.2{\%} of the cases overexpressing HER2. Moreover, at least 11.7{\%} of the cases were triple-negative. Conclusions: This study included the largest number of patients who had no concurrent breast cancer or past history of breast cancer with the longest clinical follow-up, providing insights into management practices for PLCIS and the risk of recurrence.",
keywords = "Adjuvant therapy, Breast, Local recurrence, Pleomorphic lobular carcinoma in situ",
author = "Thaer Khoury and Karabakhtsian, {Rouzan G.} and David Mattson and Li Yan and Susanna Syriac and Fadi Habib and Song Liu and Desouki, {Mohamed M.}",
year = "2014",
doi = "10.1111/his.12353",
language = "English (US)",
volume = "64",
pages = "981--993",
journal = "Histopathology",
issn = "0309-0167",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Pleomorphic lobular carcinoma in situ of the breast

T2 - Clinicopathological review of 47 cases

AU - Khoury, Thaer

AU - Karabakhtsian, Rouzan G.

AU - Mattson, David

AU - Yan, Li

AU - Syriac, Susanna

AU - Habib, Fadi

AU - Liu, Song

AU - Desouki, Mohamed M.

PY - 2014

Y1 - 2014

N2 - Aims: Pleomorphic lobular carcinoma in situ (PLCIS) of the breast is a distinctive entity, but its behaviour and management are unclear. The purpose of this study was to review a relatively large number of cases and to evaluate the risk of recurrence. Methods and results: Cases of PLCIS (n = 47) from a 12-year period were reviewed. The clinical, radiological and pathological findings were recorded. Immunohistochemistry for oestrogen receptor (ER), progesterone receptor (PR) and HER2 was performed. Thirty-one patients had no concurrent breast cancer or past history of breast cancer, and six (19.4%) of these had local recurrence; all tumours (four invasive carcinoma and two PLCIS) were ipsilateral. Younger age at presentation was a risk factor for local recurrence: patients with recurrence had a mean age (range) of 52.5 years (44-59 years), versus 60.6 years (40-81 years) for those without (P = 0.03). Three of 31 patients were treated with radiation therapy (RT), and none of these developed local recurrence. PLCIS had an adverse ER/PR/HER2 molecular profile, with at least 41.2% of the cases overexpressing HER2. Moreover, at least 11.7% of the cases were triple-negative. Conclusions: This study included the largest number of patients who had no concurrent breast cancer or past history of breast cancer with the longest clinical follow-up, providing insights into management practices for PLCIS and the risk of recurrence.

AB - Aims: Pleomorphic lobular carcinoma in situ (PLCIS) of the breast is a distinctive entity, but its behaviour and management are unclear. The purpose of this study was to review a relatively large number of cases and to evaluate the risk of recurrence. Methods and results: Cases of PLCIS (n = 47) from a 12-year period were reviewed. The clinical, radiological and pathological findings were recorded. Immunohistochemistry for oestrogen receptor (ER), progesterone receptor (PR) and HER2 was performed. Thirty-one patients had no concurrent breast cancer or past history of breast cancer, and six (19.4%) of these had local recurrence; all tumours (four invasive carcinoma and two PLCIS) were ipsilateral. Younger age at presentation was a risk factor for local recurrence: patients with recurrence had a mean age (range) of 52.5 years (44-59 years), versus 60.6 years (40-81 years) for those without (P = 0.03). Three of 31 patients were treated with radiation therapy (RT), and none of these developed local recurrence. PLCIS had an adverse ER/PR/HER2 molecular profile, with at least 41.2% of the cases overexpressing HER2. Moreover, at least 11.7% of the cases were triple-negative. Conclusions: This study included the largest number of patients who had no concurrent breast cancer or past history of breast cancer with the longest clinical follow-up, providing insights into management practices for PLCIS and the risk of recurrence.

KW - Adjuvant therapy

KW - Breast

KW - Local recurrence

KW - Pleomorphic lobular carcinoma in situ

UR - http://www.scopus.com/inward/record.url?scp=84899915163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899915163&partnerID=8YFLogxK

U2 - 10.1111/his.12353

DO - 10.1111/his.12353

M3 - Article

C2 - 24372322

AN - SCOPUS:84899915163

VL - 64

SP - 981

EP - 993

JO - Histopathology

JF - Histopathology

SN - 0309-0167

IS - 7

ER -